Bavarian Nordic A/s

Janssen Vaccines & Prevention B.v.

Janssen Sciences Ireland Unlimited Company

Markus Kalla

Robin Steigerwald

Jerôme Hubertina Henricus Victor Custers

Johannes Petrus Maria Langedijk

Ulrike Dirmeier

Frank Wegmann

Ryan Rountree

Viki Bockstal

Soumitra Roy

Selina Khan

Jerôme H H V Custers

Evelien Margaretha Bunnik

Gerrit Christiaan Scheper

Jean-Marc Edmond Fernand Marie Neefs

Daniel Boden

Helen Horton

Roland Christian Zahn

Katrin Weidner

Poxvirus vectors encoding a synthetic HIV envelope antigen and other HIV antigens, as well as compositions containing such poxvirus vectors and uses of such poxvirus vectors as vaccines to provide improved immunity against HIV, are provided. Also provided are vaccine combinations containing the disclosed poxvirus vectors, adenovirus vectors encoding one or more HIV antigens, and one or more isolated HIV antigenic polypeptides, and methods of using the vaccine combinations to provide improved immunity against HIV.

Poxvirus vectors encoding HIV antigens, and methods of use thereof

Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses. More particularly, the recombinant poxviruses comprise one or more modified nucleic acids encoding MUC1, CEA, and/or TRICOM antigens, wherein the recombinant poxviruses are stable through successive passaging. Also, provided herein are compositions and method related thereto.

Compositions and methods for enhancing the stability of transgenes in poxviruses

The present invention relates to recombinant modified vaccinia virus Ankara (MVA) and to methods of using the same. In particular, the invention relates to recombinant MVA comprising a nucleotide sequence encoding for a structural protein of an equine encephalitis virus (EEV) excluding encoding for a capsid protein of the EEV, a composition in particular a pharmaceutical composition, a vaccine or kit comprising the recombinant MVA, uses and methods thereof e.g., suitable for treating and/or preventing a western, Venezuelan, and/or eastern equine encephalitis virus caused disease.

Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine

The present invention relates to modified poxviral vectors and to methods of making and using the same. In particular, the invention relates to recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against FMDV infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a FMDV protein. The invention also relates to products, methods and uses thereof, e.g., suitable to induce a protective immune response in a subject.

Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine

Provided herein are Modified Vaccinia Ankara (MVA) vectors and adenovirus vectors encoding HBV antigens. Also provided are methods of enhancing an immune response in a human subject by utilizing the MVA and adenovirus vectors encoding HBV antigens in a prime/boost regimen to the enhance the immune response in the human subject.

Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)

Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine

Vectors, vaccines, vaccine compositions and vaccine combinations for use as therapeutics against HPV18 and/or HPV16 are described.

Therapeutic HPV vaccine combinations

Growing community of inventors

Penzberg, Germany

Markus Kalla